IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%
Market cap
$43.1B
P/E
39.1×
Fwd P/E
38.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. (IDXX) Net income

Alert me on Net income

IDEXX Laboratories, Inc.'s net income for fiscal 2025 was $1.1B, up 19.3% from $887.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.1B. Over the past ten years it has ranged from $192.1M (fiscal 2015) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. IDEXX Laboratories, Inc. ranks 5th of 52 Diagnostics & Research companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 $1.1B 19.33%
FY2024 $887.9M 5.07%
FY2023 $845.0M 24.44%
FY2022 $679.1M (8.83%)
FY2021 $744.8M 27.95%
FY2020 $582.1M 36.08%
FY2019 $427.8M 13.46%
FY2018 $377.0M 43.22%
FY2017 $263.3M 18.56%
FY2016 $222.1M 15.57%

Quarterly newest first

Period Net income Change
Jun 2026 $338.4M 21.54%
Mar 2026 $278.4M 12.19%
Dec 2025 $248.2M (9.62%)
Sep 2025 $274.6M (6.59%)
42 more quarters

Against its own ten years

Low $192.1M High $1.1B
Ten-year median $582.1M
Current reading's percentile 100

Net income against peers

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on IDXX